Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2026)

Recursion Pharmaceuticals has reported Receivables - Other for 6 years, with the latest figure at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 119.11% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (up 119.11% YoY), and the FY2025 full-year result was $24.6 million, up 212.01% from the prior year.
• Receivables - Other for Q1 2026 stood at $13.6 million, down from $24.6 million in the prior quarter.
• The five-year high for Receivables - Other was $49.2 million in Q4 2024, with the low at $2.1 million in Q1 2023.
• Historically, Receivables - Other has averaged $11.6 million across 5 years, with a median of $6.2 million in 2025.
• Annual changes were most pronounced in 2023 — Receivables - Other plunged 81.9% — and 2024, when it surged 1489.08%.
• Recursion Pharmaceuticals' Receivables - Other stood at $2.8 million in 2022, then grew by 12.39% to $3.1 million in 2023, then surged by 1489.08% to $49.2 million in 2024, then sank by 49.87% to $24.6 million in 2025, then slumped by 44.89% to $13.6 million in 2026.
• The last three Receivables - Other figures came in at $13.6 million (Q1 2026), $24.6 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.